Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Heron Therapeutics (HRTX) EBIAT (2016 - 2025)

Heron Therapeutics' EBIAT history spans 14 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, EBIAT fell 180.64% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$20.2 million, down 48.71%, while the annual FY2025 figure was -$20.2 million, 48.71% down from the prior year.
  • EBIAT reached -$3.0 million in Q4 2025 per HRTX's latest filing, up from -$17.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $3.7 million in Q4 2024 to a low of -$63.9 million in Q1 2022.
  • Average EBIAT over 5 years is -$27.4 million, with a median of -$22.4 million recorded in 2022.
  • The largest YoY upside for EBIAT was 183.39% in 2025 against a maximum downside of 260.87% in 2025.
  • A 5-year view of EBIAT shows it stood at -$54.6 million in 2021, then soared by 63.64% to -$19.9 million in 2022, then soared by 46.03% to -$10.7 million in 2023, then surged by 134.16% to $3.7 million in 2024, then plummeted by 180.64% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's EBIAT are -$3.0 million (Q4 2025), -$17.5 million (Q3 2025), and -$2.4 million (Q2 2025).